Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

Sylvie Lorenzen

Thorsten Oliver Goetze

Peter C. Thuss-Patience

Jorge Riera-Knorrenschild

Eray Goekkurt

Tobias Nicolaas Dechow

Thomas Jens Ettrich

Ralf Dieter Hofheinz

Kim Barbara Luley

Daniel Pink

Udo Lindig

Gunnar Folprecht

From Bielefeld University, Medical School and University Medical Center Ostwestfalen-Lippe, Campus Hospital Lippe, Detmold, Germany (J.H.); the Department of Radiation Oncology, Medical University of Graz, Graz, Austria (T.B.); the Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany (C.S.); the Institute of Surgical Pathology, University Medical Center Freiburg, Germany (P.B.); the Department of Surgery, University Medical Center Schleswig-Holstein–Campus Lübeck, Lübeck, Germany (B.K., T.K.); Comprehensive Cancer Center Augsburg, Faculty of Medicine, University of Augsburg, Augsburg, Germany (R.C.); the Department of General and Visceral Surgery, University Medical Center Freiburg, Freiburg, Germany (S.U.); the Department of General, Visceral, and Thoracic Surgery, University Medical Center Hamburg–Eppendorf, Hamburg, Germany (J.R.I.); the Department of Gastrointestinal Surgery, IRCCS San Raffaele Scientific Institute and San Raffaele Vita-Salute Universi...

Gunter Schuch

Michael Bitzer

Volker Heinemann

Stefan Angermeier

Claus Bolling

Maria Loose

Sabine Junge

Claudia Pauligk

Salah-Eddin Al-Batran

Krankenhaus Nordwest, University Cancer Center (UCT) Frankfurt, and Frankfurt Institute of Clinical Cancer Research (IKF), Frankfurt, Germany